NCT06893510 Virtual Reality-Based and Face-to-Face Relaxation Programs in Pregnant Women With Preeclampsia
| NCT ID | NCT06893510 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istanbul University - Cerrahpasa |
| Condition | Pre-Eclampsia |
| Study Type | INTERVENTIONAL |
| Enrollment | 96 participants |
| Start Date | 2025-09-08 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 96 participants in total. It began in 2025-09-08 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Preeclampsia, affecting 2-8% of pregnancies globally, is a leading hypertensive disorder in pregnancy. It is clinically characterized by elevated blood pressure (≥140/90 mmHg) after the 20th gestational week, often accompanied by proteinuria and systemic complications such as thrombocytopenia, liver dysfunction, and cerebral symptoms. This condition poses significant risks for both maternal and fetal health, increasing the likelihood of organ damage, preterm birth, and long-term cardiovascular and neurodevelopmental complications. Non-pharmacological interventions, including relaxation techniques, have been explored for symptom management. Progressive muscle relaxation (PMR) has shown efficacy in reducing stress, anxiety, and blood pressure. Recently, virtual reality (VR)-based relaxation techniques have gained attention for enhancing stress relief and improving health outcomes. This study aims to compare the effects of VR-based PMR with in-person PMR on maternal and fetal outcomes in preeclamptic pregnancies.
Eligibility Criteria
Inclusion Criteria: * Hospitalized with a diagnosis of preeclampsia. * Gestational age ≥26 weeks. * 18 years or older. * Singleton and viable pregnancy. * Willing to participate in the study voluntarily. Exclusion Criteria: * Multiple pregnancy. * Pregnancy achieved through assisted reproductive technologies. * Hearing or vision impairment in the pregnant individual. * Fetal distress requiring emergency intervention. * HELLP Syndrome or Eclampsia. * History of vertigo. Withdrawal Criteria: * Cases where live birth does not occur. * Participants who voluntarily withdraw from the study. * Participants whose general health condition deteriorates during the intervention. * Participants experiencing side effects from virtual reality headset use (e.g., dizziness, nausea, headache). * Participants who do not practice progressive muscle relaxation at least once a week after the intervention.
Contact & Investigator
Ergül Aslan, Prof. Dr.
PRINCIPAL INVESTIGATOR
İstanbul University-Cerrahpaşa
Frequently Asked Questions
Who can join the NCT06893510 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Pre-Eclampsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06893510 currently recruiting?
Yes, NCT06893510 is actively recruiting participants. Contact the research team at guzin.unlu@ogr.iuc.edu.tr for enrollment information.
Where is the NCT06893510 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT06893510 clinical trial?
NCT06893510 is sponsored by Istanbul University - Cerrahpasa. The principal investigator is Ergül Aslan, Prof. Dr. at İstanbul University-Cerrahpaşa. The trial plans to enroll 96 participants.